Jump to content

DPruden

Members
  • Content count

    172
  • Joined

  • Last visited

  • Days Won

    6
  • Country

    United States

DPruden last won the day on November 17

DPruden had the most liked content!

About DPruden

  • Rank
    Senior Member
  • Birthday 01/10/1970

Profile Information

  • Gender
    Not Telling
  • Interests
    Skiing, traveling and reading.
  • Biography
    I am an R2r who is lucky not to have had HDN, pre-rhogam O negative mom and an older B positive sibling.
  • Location
    Denver
  • Occupation
    Chief Medical Lab Scientist-Blood Bank
  • Real Name
    Dianna
  1. I just answered this question. My Score PASS  
  2. I just answered this question. My Score PASS  
  3. BloodBankTalk:Allergic Reaction

    I just answered this question. My Score PASS  
  4. The INR was never intended to predict bleeding risk, it was intended to normalize PT results from lab to lab in order to provide physicians a more standard indication of their patient's anticoagulation status. There was a good presentation at AABB by Dr. Mary Townsend about this topic in the Blood Bank Mythbusters session.
  5. Daily Reagent QC requirements

    Did they say where in the CFR?
  6. Blood Bank Software

    Don't let the Beaker/Epic people tell you that only one day of training is sufficient for SafeTrace Tx. And ask to have the Beaker training and Tx training environments interfaced because the steps are much different when the information is interfaced as opposed to being just typed into Tx. Also, have someone verify the ADT/visit setup, when we went live, Epic would send a "discharge/transfer" notice across the interface whenever the patients were moved, to OR or radiology, for example. then Tx would discharge the patient and inactivate the sample, not the most ideal scenario when a patient is going to OR... We didn't see it during the validation because the test patients stayed nicely in their rooms the whole time!
  7. Maximum Irradiation Dose

    thanks! I found it in the Technical Manual, both European and US references.
  8. From the fact book: the occurrence of haplotype r' (Ce) is 2% in all population groups listed (Caucasian, Black, Native Americans, Asians) haplotype r" (cE) is 1% Caucasian, 0% Black, 6% Native American,0% Asian and ry (CE) is essentially 0% in all populations, of course that includes D+ populations. r'r' and r"r" are rare across all populations. r'r is 0.8% occurrence for Caucasian, rare for Black, 0.1% for Asian. r"r is 0.9% occurrence for Caucasian, rare for Black, rare for Asian.
  9. Does anyone know if there is a maximum dose for irradiating blood products? I have looked all over the FDA/CBER website and can't find anything.
  10. Daily Reagent QC requirements

    We do not run a negative control unless specifically instructed to by the package insert. We use corQC and haven't had a problem, the only individual reagent that we have that even recommends a negative control is the anti-D.
  11. I was overthinking. Thanks for the feedback!
  12. Extending specimens past 3 days

    We do the same.
  13. I was hoping someone else could tell me how they handle proficiency testing surveys if you have different instruments. We currently have 2 ECHOs and 1 NEO, and I am in a quandary on how to do the JAT survey on both instruments without breaking the rules about repeating CAP samples before the due date. We don't really have a designated first choice of instruments and the JAT samples are stated by CAP to run within 7 days of receipt due to the possibility of hemolysis. Thanks in advance!
  14. Massive Transfusion Protocol

    Both CAP and AABB reference having an MTP protocol (AABB is more specific). Massive transfusions aren't always trauma patients, so it is important to document what you would do in the unlikely event that you needed to massively transfuse a patient. 5.19.5 Massive Transfusion The BB/TS shall have a policy regarding compatibility testing when, within 24 hours, a patient has received an amount of blood approximating or greater than the total blood volume. TRM.40770 Life-Threatening Situations Phase II Adequate policies and procedures have been established for the investigation and handling of life-threatening situations (such as the use of uncrossmatched blood or abbreviation of testing) that include the written authorization of a qualified physician. NOTE: Written policies and procedures must be available to expedite testing for transfusion in a life-threatening situation. If an institution's procedure allows abbreviated testing in massive transfusion situations, records should indicate that the procedure was followed. Records must include the authorization by a qualified physician. (If approved by the institution and recorded in the laboratory's procedures, the physician responsible for the transfusion service laboratory may accept this responsibility.) If an incompatibility is discovered on completion of an incomplete crossmatch, the responsible physician must be notified in a timely manner and this notification recorded. Red blood cells released before testing has been completed must be conspicuously labeled as uncrossmatched on the tag or label. Records of completion of compatibility testing for units released uncrossmatched must be maintained.
  15. FDA reportable Question

    This is FDA reportable. Multiple reasons why: loss of control over the correct product, failure to follow your SOP, and the computer (most of them) runs final safety checks upon issuing in the computer. These are always slightly annoying to report, but as Marianne said better to err on the side of caution.
×